Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Radiosurgery 73Magnetic Resonance Spectroscopy 48Standard of Care 41Radiotherapy 36Exercise 36Blood Specimen Collection 28Early Intervention, Educational 26Surveys and Questionnaires 24Multiparametric Magnetic Resonance Imaging 22Magnetic Resonance Imaging 21Brachytherapy 21Androgen Antagonists 20Methods 19Therapeutics 18Radiotherapy, Intensity-Modulated 18Interviews as Topic 18Cystectomy 16Educational Status 15Biopsy 15Psychiatric Rehabilitation 14Practice Guidelines as Topic 14Diet Therapy 14Sunitinib 12Specimen Handling 12Resistance Training 12gallium 68 PSMA-11 11Radiation 11Watchful Waiting 9Surgical Procedures, Operative 9Proton Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Darbepoetin alfa × Genitourinary × Clear all
NCT06184867 2026-03-06

CATALYST

Rutgers, The State University of New Jersey

Phase NA Completed
50 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡